Trastuzumab emtansine for residual invasive human epidermal growth receptor-2-positive breast cancer
Saved in:
| Main Authors: | Joydeep Ghosh, Atul Batra, Amol Patel, Prashant Mehta |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2020-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=5;spage=652;epage=653;aulast=Ghosh |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ado-trastuzumab emtansine – The monoclonal drug conjugate in human epidermal growth factor receptor 2-positive breast cancer
by: Sandip Ganguly, et al.
Published: (2020-01-01) -
Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience
by: Neda Yaghoubi, et al.
Published: (2025-05-01) -
Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
by: Negar Pourjamal, et al.
Published: (2025-03-01) -
Trastuzumab: A milestone in human epidermal growth factor receptor 2-positive breast cancer
by: Manikandan Dhanushkodi
Published: (2020-01-01) -
Dynamics of sequencing of cyclin-dependent kinase inhibitors and cost expenditure analysis in the management of metastatic hormone-receptor positive, human epidermal growth factor 2-negative advancedbreast cancer
by: Amol Patel, et al.
Published: (2019-01-01)